Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06111482
Other study ID # EUN-PL01-2023
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 28, 2023
Est. completion date February 2025

Study information

Verified date October 2023
Source Cynosure, Inc.
Contact Jamie Trimper
Phone 9782564200
Email jamie.trimper@cynosure.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of the energy-based devices used in this study is to evaluate their safety and performance to treat unwanted dermatologic conditions.


Description:

Up to 50 subjects will be enrolled at 1 study center. Subjects will be enrolled into 4 groups: Group A, Group B, Group C, or Group D. Subjects may enroll in more than one group, however the last treatment in the previous group would be at least 30 days before the subject is enroll in the next group if treatment area is the same.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date February 2025
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria: - A healthy male or female 22 years of age or older. - Willing to undergo at least 1 treatment with the study device(s). - Understands and accepts obligation not to receive any other procedures in the treatment area through the length of the study. - Understands and accepts the obligation and is logistically able to be present for all visits. - Is willing to comply with all requirements of the study and sign the informed consent document Exclusion Criteria: - Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period. - Takes or has taken oral isotretinoin, such as Accutane®, within the last six months. - Is using systemic steroids (e.g., prednisone, dexamethasone) prior to or during the course of treatment. - Is receiving or has received gold therapy. - Is taking medications that alter the wound-healing response or has a history of healing problems. - Has an active localized or systemic infection, or an open wound in area being treated. - Has a significant systemic illness, such as lupus, or an illness localized in area being treated. - Has a seizure disorders triggered by light. - Has a history of skin photosensitivity disorders. - Has a history of hypertrophic scars or keloid formation. - Has a history of radiation therapy in area to be treated. - Received fillers or neurotoxin injections in the treatment area within the past 2 weeks. - Has had a chemical or mechanical epilation within the last six weeks. - Currently enrolled in an investigational drug or device trial or has received an investigational drug or been treated with an investigational device within the area to be treated 6 months to entering this study. - Has any condition or is in a situation which in the investigator's opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation. Radiofrequency Device Only: - Has a Pacemaker - Has any embedded electronic devices that give or receive a signal. - Has electronic implants, such as Implantable Cardiac Defibrillators (ICD) or Cardiac Resynchronization Therapy (CRT) devices: treatment may interfere with the functionality of the device and/or damage the electronic implant. - Is allergic to adhesives such as glues on medical tape: they should be alerted that a rash may occur on the neutral electronic monitoring pad (NEM or neutral pad) site, and an over-the-counter preparation may be used to treat the area. - Has nerve insensitivity to heat in the treatment area or in the neutral pad placement area. - Is allergic to topical anesthetic

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Intense pulsed light.
The intense pulsed light (IPL) will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
Radiofrequency microneedling device
The microneedling device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
Radiofrequency device
The radio frequency device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
Combined energy devices
The combined energy devices will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Locations

Country Name City State
United States Cynosure Westford Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Cynosure, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum pain reported during treatment. The maximum pain during treatment per each device will be reported on a scale of 0(none) to 10 (maximum intolerable pain). This pain is recorded during when the patient is actively treated (when the patient comes in and receives a treatment from the device). procedure (during device treatment)]
See also
  Status Clinical Trial Phase
Recruiting NCT02296450 - Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
Completed NCT06023303 - Prospective Clinical Study to Assess Safety and to Collect Data on Radiofrequency Microneedling Device(s) For the Purpose of Evaluating Treatment on Skin N/A
Recruiting NCT02471352 - Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
Completed NCT06059417 - Foam Tape Allergy a Sticky Situation N/A
Completed NCT02122432 - Teledermatology Versus Usual Care on Delay Before Diagnosis and Treatment of Dermatologic Conditions N/A